Why One Drug Company Held Back a Better Drugnews2023-09-07T10:00:12+00:00September 7th, 2023|The New York Times|
Expert Panel Recommends New Drugs for HIV Preventionnews2023-08-22T15:55:45+00:00August 22nd, 2023|The New York Times|
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapynews2023-07-22T18:26:55+00:00July 22nd, 2023|The New York Times|
When Politics Saves Lives: a Good-News Storynews2023-06-07T17:50:17+00:00June 7th, 2023|The New York Times|
Gilead Wins Key Patent Rights Suit Over HIV Prevention Drug PrEPnews2023-05-09T17:34:57+00:00May 9th, 2023|The New York Times|
The Only H.I.V. Vaccine in Advanced Trials Has Failed. What Now?news2023-01-18T21:26:06+00:00January 18th, 2023|The New York Times|
How Anthony Fauci Quietly Shocked AIDS Activistsnews2022-12-31T14:00:06+00:00December 31st, 2022|The New York Times|
Un nuevo tratamiento contra el VIH ha probado ser un éxito. ¿Será accesible en África?news2022-09-30T09:00:20+00:00September 30th, 2022|The New York Times|
A New Shot Guards Against H.I.V., but Access for Africans Is Uncertainnews2022-09-27T07:00:12+00:00September 27th, 2022|The New York Times|
McKinsey Guided Companies at the Center of the Opioid Crisisnews2022-06-29T23:24:22+00:00June 29th, 2022|The New York Times|
